Robert E. Claypoole - 10 Jan 2025 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: President and CEO, Director
Signature: /s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol: BVS
Transactions as of: 10 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 13 Jan 2025, 17:24:32 UTC
Previous filing: 12 Jan 2024
Next filing: 14 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BVS	Class A Common Stock	Options Exercise	$0	+93,750		$0.000000	93,750	10 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BVS	Restricted Stock Units	Options Exercise	$0	-93,750	-25%	$0.000000	281,250	10 Jan 2025	Class A Common Stock	93,750		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2	The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.